Table 2 Pidotimod: clinical trials in adults

Evaluation of the efficacy of Pidotimod in the exacerbations in patients affected with chronic Bronchities

181 COPD

↓Frequency of relapses

Expectoration characteristics

• M/F = 117/64

↓ to time of relapses,

↑ spirometric parameters

Mean age 62.5 years

↓ time of recovery

Pidotimod activity against chronic bronchitis exacerbation

580 COPD

↓ fewer infectious exacerbations

• Treatment group M/F = 94/31 mean age 66.2 years

↑ better response to antibiotics treatment

↓days out of work

• Placebo treatment M/F = 200/63 mean age 65.2 years

Immunological function of T-lynphocyte in the elderly with chronic obstuctive pulmonary disease during acute exacerbations medication intervention

103 COPD

↓day of hospitalization

↑ the cell immune response in elderly patients

• Elderly COPD intervention group M/F = 23/9mean age 7.1 years

↓ cost of hospitalization

↑ spirometric parameters

• Elderly COPD control group M/F = 22/12 mean age 69.9 years

• Non elderly COPD control group M/F = 15/10 mean age 56.2 years

Ex vivo evaluation of Pidotimod activity in patients with chronic obstructive pulmonary disease.

52 COPD

↑T-cells activity ↑stimulate macrophages and granulocytes

• Treatment group

M/F = 13/13 mean age 65.92

• Control group M/F = 10/16 mean age 62.46

Treatment of 30 cases of senile pneumonia with Pidotimod.

62 elderly with pneumonia

↓n° of recovery

↑ neutrophilic bactericidal

↑ bacterial eradication

↑ IgG level

• M/F = 33/29

• Mean age 72 years

Valutazione dell’attività del Pidotimod sulla secrezione di IgA in pazienti affetti da BPCO

20 COPD

↑of secretory IgA in the sputum,

• From 40to 75 years

a stabilization of the level.

Valutazione sperimentale controllata dell’attività di Pidotimod in paziente affetti da BPCO

85 COPD

↓ number of exacerbations

• M/F = 54/31

Pidotimod activity against chronic bronchitis exacerbations

580 COPD

↓number of infectious exacerbations

• Treatment group M/F 94/31 mean age 66.2 years

↓duration of Exacerbations

↓duration of therapy

• Control group

M/F = 200/63 mean age 62.46 years

Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels.

21patients

↑of the concentration of salivary IgA

• M/F = 12/10

• mean age 41 years

Treatment of 30

62 patients

↓ number of hospitalization

↑ neutrophilic activity

cases of senile pneumonia with Pidotimod

• M/F = 33/29

↑level of IgG

• Mean age 72 years

Pidotimod nel trattamento delle faringotonsilliti recidivanti

40 adults + children with recurrent pharingotonsillitis

↓ recurrent of upper respiratory

↑ of immune-response on Multitest

• M/F = 13/21

• Mean age 23.2 years